API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
FDA has cleared the IND for S-217622, a once-daily investigational 3CL protease inhibitor oral antiviral therapy, enabling the global phase 3 trial to proceed as part of the ACTIV-2 program for COVID-19.
Lead Product(s): Ensitrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: S-217622
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Shionogi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
S-217622 suppresses the duplication of SARS-CoV-2 by selectively inhibiting 3CL protease, an orally administered antiviral drug for COVID-19, caused by the novel coronavirus (SARS-CoV-2).
Lead Product(s): Ensitrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: S-217622
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2021